Series A+ · BiotechVivacta Biotechnology: Series A+Develops in vivo CAR-T cell therapies for cancer and autoimmune diseasesPublished Oct 4, 2026By RoundOS Funding deskFunding historyApr 29, 2026Series A+ · This round$50MSourcesprnewswire.com↗
Guoke Brain-ComputerBeijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.UndisclosedSeed · Oct 23, 2026
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200MPrivate financing · Oct 23, 2026
Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237MSeries E · Oct 23, 2026
Warp SciencesWarp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.$215MSeries A · Oct 22, 2026